A Rollover Protocol of Dacomitinib For Patients In Japan
Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study to permit continued access to dacomitinib for patients who
participated in other dacomitinib monotherapy treatment protocols in Japan and have the
potential to derive clinical benefit without unacceptable toxicity from continued dacomitinib
treatment.